9,096 Shares in Lantheus Holdings, Inc. $LNTH Purchased by Havemeyer Place LP

Havemeyer Place LP purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,096 shares of the medical equipment provider’s stock, valued at approximately $605,000.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in shares of Lantheus by 30.3% during the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 230 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares in the last quarter. Resona Asset Management Co. Ltd. grew its holdings in shares of Lantheus by 35.7% in the fourth quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 292 shares in the last quarter. Parallel Advisors LLC increased its position in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the last quarter. Finally, Verdence Capital Advisors LLC raised its stake in Lantheus by 3.8% during the fourth quarter. Verdence Capital Advisors LLC now owns 8,455 shares of the medical equipment provider’s stock valued at $563,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LNTH shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Mizuho upped their target price on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, May 27th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Truist Financial reissued a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Down 1.0%

NASDAQ LNTH opened at $100.01 on Tuesday. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $104.00. The firm has a market capitalization of $6.51 billion, a price-to-earnings ratio of 24.10 and a beta of -0.03. The company has a fifty day moving average of $88.48 and a two-hundred day moving average of $75.44.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, analysts predict that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.